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Abstract—TheWorld Federation for Ultrasound inMedicine and Biology (WFUMB) has produced these guidelines
for the use of elastography techniques in liver disease. For each available technique, the reproducibility, results, and
limitations are analyzed, and recommendations are given. Finally, recommendations based on the international
literature and the findings of theWFUMB expert group are established as answers to common questions. The docu-
ment has a clinical perspective and is aimed at assessing the usefulness of elastography in the management of liver
diseases. (E-mail: m-kudo@med.kindai.ac.jp)  2015 Published by Elsevier Inc. on behalf of World Federation
for Ultrasound in Medicine & Biology.
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Diffuse liver disease is a major health problem world-
wide. Awide range of liver insults (chronic viral hepatitis,
alcoholic and non-alcoholic fatty liver disease, autoim-
mune hepatitis drug-induced liver injury, primary biliary
cirrhosis and several rarer causes) set up a common
pathway of fibrosis, which, if the damage continues, pro-
gresses and leads to cirrhosis which may be complicatedCorresponding author:Masatoshi Kudo,M.D., Ph.D., Department
astroenterology and Hepatology, Kinki University School of Med-
e, Japan, TEL: 81-72-366-0221, FAX: 81-72-367-2880 E-mail:
udo@med.kindai.ac.jp
1161by portal hypertension, liver failure and the development
of hepatocellular carcinoma.
Accurate staging of the degree of fibrosis is essential
in planning therapy (including antiviral therapy) and pre-
dicting response to treatment and malignant potential.
Although liver biopsy has long been the gold standard,
it is an invasive procedure with potential complications
such as bleeding and severe pain (Bravo et al. 2001;
Cadranel et al. 2000). In addition, sampling error is an
intrinsic problem because of the small sample size
taken from a heterogeneous organ (Cholongitas et al.
2006), and diagnostic consistency may be influenced by
interobserver variability (Maharaj et al. 1986; Bedossa
et al. 2003; Regev et al. 2002).
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opment of noninvasive techniques for the diagnosis of
liver fibrosis. There are many reports on the use of blood
markers for liver fibrosis, such as platelets, hyaluronic
acid, type IV collagen, aminotransferase/platelet ratio
index (APRI), and algorithm-based serum models (such
as Fibro Index, FIB-4, and Fibro Test) (Martinez et al.
2011a). However, these methods can be affected by fac-
tors unrelated to the liver.
As chronic liver damage results in hepatic fibrosis
characterized by an increase of extracellular matrix pro-
duced by fibroblast-like cells, the liver becomes stiffer
than normal.
Elastography can be used to assess liver stiffness
noninvasively. It measures tissue behavior when a me-
chanical stress is applied using ultrasound (US) or mag-
netic resonance imaging.
Several US-based elastography techniques are avail-
able and have been extensively described in Part 1.
Table 1 lists those that are in clinical use. They differ in
the physical properties used.
SHEAR WAVE-BASED techniques measure the
speed of shear waves in tissues. The shear waves can be
generated by an external push (transient elastography)
or by ultrasound radiation force enabling a single mea-
surement (point shear wave speed measurement) or an
image (shear wave speed imaging). The main difference
between these techniques is that shear wave speed, being
linked with stiffness, can be measured and converted into
kPa, the unit of Young’s modulus whereas strain elastog-
raphy gives relative estimates only.
STRAIN IGINGmeasures the deformation of tissue.
The European Federation of Societies for Ultrasound
in Medicine and Biology (EFSUMB) has recently issued
guidelines and recommendations on the clinical use of ul-
trasound elastography (Bamber et al. 2013; Cosgrove et al.
2013). Accordingly, our objectives are to determine based
on the evidence whether elastography is useful and
reproducible in the evaluation of diffuse liver disease, in
particular, in terms of the accuracy and limitations of the
available techniques depending on the indications and
etiologies. The impact of elastography on liver biopsy
(reduction and/or replacement) for diffuse liver disease
will be discussed. Finally, we discuss the potential role
of elastography in the characterization of focal liver
diseases.Table 1. Elastography methods in clinical use for the
liver.
1- Shear wave speed
techniques
Transient elastography
Point shear wave speed measurement
Shear wave speed imaging
2- Strain/displacement
techniques
Strain elastographyTRANSIENT ELASTOGRAPHY
Procedure
Transient elastography (TE) is performed on a pa-
tient lying supine, with the right arm elevated to facilitate
access to the right liver. The tip of the probe is in contact
with the intercostal skin through a coupling gel in the 9th
to 11th intercostal space at the level where a liver biopsy
would be performed. The operator, assisted by a time-
motion image, locates a liver portion at least 6 cm deep
and free of large vascular structures. The operator then
presses the probe button to start the measurements
(‘‘shots’’). TE measures the liver stiffness in a volume
that approximates a cylinder 1 cm wide and 4 cm long,
between 25 mm and 65 mm below the skin surface
(Figure 1). The software determines whether each mea-
surement is successful or not. When a shot is unsuccess-
ful, the instrument does not return a value. The entire
procedure is considered to have failed when no values
are obtained after ten shots. Successful measurements
are validated using the following criteria: 1) number of
valid shots$ 10; 2) ratio of valid shots to the total number
of shots $ 60%; and 3) interquartile range (IQR, reflect-
ing the variability of measurements) less than 30% of the
median liver stiffness measurement (LSM) value (IQR/
LSM #30%) (Castera et al. 2008).
TE is a user-friendly procedure: it only requires a short
time (,5 minutes) and can be performed at the bedside or
in an outpatient clinic. The results, expressed in kilopascals
(kPa) and ranging from 2.5 to 75 kPa, are available imme-
diately. Finally, it is not a difficult procedure to learn and
can be performed by a nurse after minimal training (about
100 examinations) (Boursier et al. 2008a). Nevertheless,
the clinical interpretation of TE results should be always
in the hands of an expert clinician and should be made
with full knowledge of the patient demographics, disease
etiology and essential laboratory parameters.
Reproducibility. Two independent groups (Boursier
et al. 2008b; Fraquelli et al. 2007) have evaluated its
reproducibility. In the earlier study (Fraquelli et al.
2007), the reproducibility of TE was excellent for both
inter-observer and intra-observer agreement, with an in-
traclass correlation coefficient (ICC) of 0.98. However,
interobserver agreement was significantly lower in pa-
tients with lower degrees of hepatic fibrosis (ICC for
F0-F1 0.60 vs. 0.99 for F $ 2), with hepatic steatosis
(ICC for steatosis $ 25% of hepatocytes 0.90 vs. 0.98
for ,25%) and those with increased body mass index
(ICC for BMI $ 25 kg/m2 0.94 vs. 0.98 for ,25 kg/
m2). Consistent results were reported by Boursier et al.
(2008) in a series of 46 patients examined by 4 different
operators, suggesting that the ideal candidate for TE is a
lean patient with severe fibrosis.
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Figure 1. (Adapted from Castera et al. 2008).
a. Position of probe and explored volume (Imaging from Echosens).
b. Shear wave propagation according to the severity of hepatic fibrosis (Metavir score). The elastic modulus E expressed
as E5 3rV2, where V is the shear velocity and r is the mass density (constant and close to 1 kg/m3 for tissue): the stiffer
the tissue, the faster the shear wave propagates. In the absence of fibrosis (F0), the velocity is 1.0 m/s and elasticity is 3 kPa
whereas with cirrhosis (F4), the velocity is 3.0 m/s and elasticity is 27 kPa.
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have been examined in 429 healthy subjects without overt
causes of liver disease and normal liver enzymes, who
were undergoing a medical check-up (Roulot et al.
2008). The mean liver stiffness value in these patients
was 5.561.6 kPa. Age had no influence but, as suggested
previously (Corpechot et al. 2006a), liver stiffness values
were higher in men than in women (5.861.5 vs. 5.261.6
kPa, p50.0002) and in subjects with BMI.30 kg/m2
(6.361.9 vs. 5.461.5 kPa, p50.0003). However, even af-
ter adjustment for gender and BMI, liver stiffness valuesremained higher in 59 subjects with the metabolic syn-
drome (6.561.6 vs. 5.361.5 kPa, p,0.0001). In a more
recent study of 746 Italian subjects analyzed according
to the absence (602) or presence of fatty liver (144) at
ultrasonography, liver stiffness was significantly lower
in normal livers without steatosis than in fatty livers
(median 4.4 vs. 5.3 kPa, p,0.001), and male gender
was associated with increased liver stiffness (Colombo
et al. 2011). However, all these studies were conducted
in developed countries. Recent data from India, using a
populations-based approach in 437 healthy subjects,
1164 Ultrasound in Medicine and Biology Volume 41, Number 5, 2015suggest that in healthy individuals, undernutrition and
leanness (lower BMI), increase liver stiffness values in
a similar way to obesity, providing a U-shaped distribu-
tion of normal liver stiffness values (Das et al. 2012).
Results
1. Diagnostic performances for staging liver
fibrosis. Viral hepatitis and HIV coinfection. Two index
studies suggest the value of TE in the assessment of liver
fibrosis in patients with chronic hepatitis C (Castera et al.
2005; Ziol et al. 2005). Liver stiffness values correlated
strongly with Metavir fibrosis stages. However, despite
high area under the receiver operator characteristic
curve (AUROC) values, a substantial overlap in liver
stiffness between adjacent stages of hepatic fibrosis was
observed, particularly for lower stages. Many other
groups have confirmed these results (Arena et al.
2008a; Degos et al. 2010; Lupsor et al. 2008; Zarski
et al. 2012), also in hepatitis B (Chan et al. 2009; Coco
et al. 2007; Degos et al. 2010; Marcellin et al. 2009;
Oliveri et al. 2008) and HIV-HCV coinfection (de
Ledinghen et al. 2006; Kirk et al. 2009; Pineda et al.
2009; Vergara et al. 2007).
TE accurately discriminates cirrhosis from signifi-
cant fibrosis (AUROC 0.87–0.98; correct classification
85% to 94%) (AUROC 0.75–0.93; correct classification
from 57% to 90%). Several meta-analyses (Friedrich-
Rust et al. 2008, Shaheen et al. 2007, Talwalkar et al.
2007, Tsochatzis et al. 2011) have confirmed the better
diagnostic performance of TE for cirrhosis than for
fibrosis, with mean AUROC values of 0.94 and 0.84,
respectively (Friedrich-Rust et al. 2008). In a meta-
analysis of 40 studies (32 papers and 8 abstracts), sensi-
tivity and specificity values were 0.83 and 0.89 for
patients with cirrhosis and 0.79 and 0.78 for patients
with significant fibrosis. However, only 9 studies (1364
patients) had acceptable standards for both liver biopsy
and TE, which limits the conclusions (Tsochatzis et al.
2011).
The performance of TE is similar in patients with
HBV and HCV infection (Cardoso et al. 2012).
In the metanalysis of Chon et al. (2012), 18 studies
comprising 2,772 patients with chronic hepatitis B were
analyzed. The mean AUROC values for the diagnosis
of significant fibrosis, severe fibrosis, and cirrhosis were
0.86, 0.89, and 0.93, respectively. The estimated cutoffs
for F2, F3 and F4 were 7.9 kPa (sensitivity, 74.3%; spec-
ificity, 78.3%), 8.8 kPa (sensitivity, 74.0%; specificity,
63.8%), and 11.7 kPa (sensitivity, 84.6%; specificity,
81.5%), respectively.
Serum aminotransferases should be considered in
interpreting the results from TE in patients with hepatitis
B because elevated enzymes are associated withincreased stiffness readings (Fraquelli et al. 2011). To
avoid false positive results, some authors have proposed
using modified TE cut-offs based on ALT levels (Chan
et al. 2009) - a strategy that might not apply to patients
with fluctuating levels of ALT or hepatitis flares. Con-
versely, in hepatitis B e antigen negative patients with
normal ALT levels, non-invasive methods, particularly
TE, could be used as adjuncts to HBV DNA measure-
ments, to follow inactive carriers or better identify
patients who require liver biopsy (those with ongoing dis-
ease activity or significant fibrosis, despite normal ALT
levels) (Castera et al. 2011; Maimone et al. 2009; Ngo
et al. 2008; Oliveri et al. 2008).
NAFLD. So far, the number of studies that have
investigated TE in NAFLD patients remains limited
(Gaia et al. 2011; Nobili et al. 2008; Petta et al. 2011;
Wong et al. 2010; Yoneda et al. 2008; Wong et al.
2012; Kumar et al. 2013). TE results should be
interpreted with caution because these studies have
been conducted either in particular populations (Asian
with low BMI or pediatric population) or with small
sample size. Nevertheless, TE could be useful to
confidently exclude severe fibrosis and cirrhosis with a
high negative predictive value (approximately 90%) in
these patients (Wong et al. 2010). In a very recent
meta-analysis, 9 studies including 1,047 NAFLD patients
were compared. The analysis was performed only on the
data obtained with the M probe in 854 patients. The over-
all results suggest that TE is good in diagnosing F $ 3
(sensitivity, 85%; specificity, 82%) and F54 (sensitivity,
92%; specificity, 92%) and has moderate accuracy for F
$ 2, (sensitivity, 79%; specificity 75%) (Kwok et al.
2014).
Other liver diseases. TE has also been evaluated in
cholestatic liver diseases (Corpechot et al. 2012,
Corpechot et al. 2006b), in a variety of chronic liver
diseases (Foucher et al. 2006a; Fraquelli et al. 2007;
Ganne-Carrie et al. 2006) as well as in alcoholic liver
disease (Nahon et al. 2008; Nguyen-Khac et al. 2008).
In the study of Corpechot et al. (2012), there was a signi-
ficant association between TE and histological fibrosis
stage (P , 0.0001), but no correlation with necroinﬂam-
matory activity grade or the presence of ductopenia. It has
been suggested by several groups that the presence of
alcoholic hepatitis may influence the liver stiffness results
(Bardou-Jacquet et al. 2013; Mueller et al. 2010; Trabut
et al. 2012) and thus TE should be performed after
alcohol withdrawal to improve accuracy.
Cut-offs. TE appears as a reliable method for the
diagnosis of cirrhosis, better at excluding than at predict-
ing cirrhosis. For instance, in a population of 1,007
patients with different chronic liver diseases, a cut-off
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values of 74% and 96%, respectively (Ganne-Carrie et al.
2006). Interestingly, proposed cut-off values for cirrhosis
ranged from 11 kPa in patients with hepatitis B to 22.7
kPa in patients with alcoholic liver disease. Some re-
searchers have proposed cut-off values based on the
causes of liver disease (Ganne-Carrie et al. 2006). How-
ever, differences among cut-off values could result from
differences in the prevalence of cirrhosis among the study
populations (ranging from 8% to 25%). A cut-off value
for one population might not be applicable to another
with a different prevalence of disease. Most studies
used single cut-off values for patients with cirrhosis or
advanced fibrosis, but more information can be obtained
when values are interpreted as a continuum. For example,
when liver stiffness values range from 2.5 to 7 kPa,
fibrosis is likely mild or absent, whereas when values
are above 12.5 kPa, cirrhosis is likely (Castera et al.
2008) (Figure 2).
2. Monitoring disease progression and prog-
nosis. Portal hypertension. TE results can identify
patients most likely to develop clinically significant por-
tal hypertension, but are not able to identify patients with
esophageal varices (Castera et al. 2012). Given its likely
prognostic value for patients with cirrhosis, TE could be
used to discriminate among patients at different stages of
progression of compensated cirrhosis, and stratify them
in different risk categories.
TE has recently been used to evaluate the stiffness of
the spleen. Colecchia et al. (2012) have reported that in
patients with compensated liver cirrhosis spleen stiffness
correlates with portal pressure gradient and is accurate in
predicting esophageal varices. However, the accuracy of
spleen stiffness in ruling in or ruling out clinically signif-
icant portal hypertension or esophageal varices needs to
be validated. A recent meta-analysis including 12 studies
performed with either TE, PSWSM or magnetic reso-
nance elastography, has concluded that the accuracy is
still limited to allow its use in clinical practice (Singh
et al. 2013).75 kPa2.5 7.0 9.5 12.5
Absent or mild
fibrosis
(Metavir F0-F1)
Significant
fibrosis
(F2)
Severe
fibrosis
(F3)
Cirrhosis
(F4)
Figure 2. (Adapted from Castera et al. 2008). Clinical signifi-
cance of liver stiffness cut-offs in chronic liver diseases.
When liver stiffness values range between 2.5 and 7.0 kPa,
mild or no fibrosis is likely, whereas when liver stiffness values
are greater than 12.5 kPa, cirrhosis is likely.Hepatocellular carcinoma. Large, prospective
cohort studies in Asia of patients with hepatitis B or C
correlated liver stiffness values with HCC occurrence
(Fung et al. 2011a; Jung et al. 2011; Masuzaki et al.
2009). Among 866 Japanese patients with HCV
infection, the cumulative incidence of HCC within 3
years was as high as 38.5% among those with baseline
liver stiffness values .25 kPa, compared with 0.4%
among subjects with values #10 kPa (Masuzaki et al.
2009). Although the measurements of liver stiffness
could be used to identify patients at risk of developing
HCC, more data are needed before they can be integrated
into a HCC surveillance program.
Prognosis and survival. Recently, it has been sug-
gested that TE could be used to predict the prognosis of
patients with chronic liver disease related to viral hepatitis
or other causes (Robic et al. 2011; Vergniol et al. 2011;
Merchante et al. 2012). When compared with serum bio-
markers, TE had the highest 5-year predictive value to pre-
dict survival and liver-related death in 1,457 patients with
HCV infection, and this did not change after adjustment
for treatment response, patient age, or estimates of nec-
roinflammatory grade (Vergniol et al. 2011). Similarly,
in a cohort of 600 patients with chronic hepatitis B, the
5-year overall survival was 97.1% in patients with liver
stiffness,9 kPa, and 61.5% in patients with liver stiffness
.20 kPa. At 5 years, no liver-related death was observed
in inactive carriers, and the association of liver stiffness
with survival persisted after adjustment for potential con-
founders (age, treatment, and estimate of necroinflamma-
tory activity) (de Ledinghen et al. 2013).
Monitoring the response to antiviral treatment. In
patients already receiving antiviral therapy, TE can be
used to monitor the response and evaluate the regression
of fibrosis. Significant histologic improvements have
been documented in studies of paired liver biopsies
from patients with chronic hepatitis C who achieved sus-
tained viral eradication (Poynard et al. 2002; Shiratori
et al. 2000) and patients with chronic hepatitis B who
received long-term antiviral therapy (Chang et al. 2010;
Hadziyannis et al. 2006). Several studies reported a
significant decrease in liver stiffness values, compared
with baseline values, in patients with HCV who
achieved sustained viral eradication (Fontana et al.
2009; Hezode et al. 2011; Martinez et al. 2011b;
Ogawa et al. 2009; Vergniol et al. 2009; Stasi et al.
2013; Casado et al. 2013), as well as in HBV-infected pa-
tients treated with nucleoside analog drugs (Enomoto
et al. 2010; Fung et al. 2011b; Lim et al. 2011; Ogawa
et al. 2011; Osakabe et al. 2011; Wong et al. 2011; Kim
et al. 2013; Kuo et al. 2014).
Despite these encouraging results, following the
progress of treated patients with TE can be confounded
1166 Ultrasound in Medicine and Biology Volume 41, Number 5, 2015by changing levels of ALTand inflammation. Similarly, a
decrease in liver stiffness could result from reductions in
inflammatory activity, rather than fibrosis. However, in
the only study (Hezode et al. 2011) that assessed liver
stiffness kinetics at multiple time points during (weeks
4 and 12) and after therapy (week 24), liver stiffness
decreased significantly with treatment among all patients
but only continued to decrease significantly after the
end of treatment in those patients with sustained viral
eradication.Limitations
Applicability: failure and unreliable results. TE
can be difficult in obese patients or those with narrow
intercostal space and cannot technically be performed
in patients with ascites (Sandrin et al. 2003).
In an initial trial of 2114 examinations, failure
occurred in 4.5% of cases (Foucher et al. 2006b). In a
multivariate analysis, the only factor associated with fail-
ure was obesity (body mass index . 28 kg/m2 (OR 10.0
(95% CI 5.7-17.9), p50.001). Updating this experience
with more than 13,000 examinations in 7,261 patients
seen over a 5 years period, failure to obtain any measure-
ment was observed in 4% of examinations and unreliable
results in 17% (Castera et al. 2010). Thus, TE was not
successful in almost 20% of cases. In the multivariate
analysis, failure and unreliable results were associated
with obesity and limited operator experience. However,
a fatty thoracic belt, not a fatty mass index, was a limiting
factor for the success rate. Indeed, when metabolic syn-
drome and waist circumference were taken into account
in a subgroup of 2,835 patients, waist circumference
was the most important determinant of unreliable results
and LSM failure.
Whether unreliable results translate into decreased
accuracy is an important question in clinical practice. It
has been suggested that among the recommendations,
the IQR/LSM .30% is the most important for good
diagnostic accuracy (Lucidarme et al. 2009; Myers
et al. 2010). In 1165 patients with chronic liver
diseases (798 with chronic hepatitis C), Boursier et al.
(2013) found no difference in the overall diagnostic ac-
curacy. In a multivariate analysis, they found that
fibrosis staging was independently associated with the
median liver stiffness and IQR/LSM for all stages and
proposed new reliability criteria: very reliable: IQR/M
, 0.10; reliable: IQR/M 0.10–0.30 or IQR/M .0.30
and median liver stiffness ,7.1 kPa; and poorly
reliable: IQR/M .0.30 and median liver stiffness
.7.1 kPa. Using these new criteria, only 9.1% of the ex-
aminations were unreliable. These results warrant
further validation.Confounding factors. The liver is encapsulated in a
distensible but stiff envelope (Glisson’s capsule), such that
additional space-occupying changes, such as edema,
inflammation, extra-hepatic cholestasis, or congestion,
can increase its stiffness and elevate the measurements,
independently of fibrosis. The extent of necro-
inflammatory activity has been shown to influence TE
measurements in patients with viral hepatitis, with a
steady increase of liver values in parallel with the degree
of histological activity (Arena et al. 2008b; Chan et al.
2009; Fraquelli et al. 2007). Consistent with these
results, overestimation of liver stiffness has been
reported during ALT flares in patients with acute viral
hepatitis or chronic hepatitis B (Arena et al. 2008b;
Coco et al. 2007; Sagir et al. 2007) as well as in cases of
extrahepatic cholestasis (Millonig et al. 2008) or conges-
tive heart failure (Millonig et al. 2010). The influence of
steatosis is still a matter of debate because of conflicting
results: some studies suggest a detrimental effect (Gaia
et al. 2011) whereas others do not (Wong et al. 2010).
Influence of food intake. Food intake increased liver
stiffness values in patients with cirrhosis and portal hyper-
tension, and in healthy controls (Mederacke et al. 2009;
Arena et al. 2013, Berzigotti et al. 2013), thus patients
should fast before TE (and all liver elastography)
examinations.
Recommendations
 The interpretation of TE results should always be in the
hands of an expert clinician and should bemade in light
of the patient demographics, disease etiology and key
laboratory findings, as well as according to the manu-
facturer’s recommendations, particularly the IQR/M
ratio, which should be less than 30%.
 The main limitation to the use of TE in clinical practice
is its limited applicability in obese patients. The use of
the XL probe reduces the failure rate in obese patients
but results in a high rate of unreliable results (approx-
imately 25%). The clinical value of unreliable results
remains a matter of debate.
 TE cannot be performed in patients with ascites.
 Several factors, including acute hepatitis, cholestasis,
liver congestion, and food intake, increase the liver
stiffness. Therefore, TE should be performed in fasting
patients, and avoided or interpreted cautiously in pa-
tients with elevated transaminases (.5 x upper limit
of normal), cholestasis, congestive cardiac failure,
ongoing alcohol intake or alcoholic hepatitis.
 TE has been well validated in chronic viral hepatitis
(C better than B) and can confidently be used as first
line method for staging liver fibrosis. This strategy re-
mains to be validated for other liver diseases.
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creases the diagnostic accuracy for significant fibrosis
in patients with chronic hepatitis C, a strategy that
needs to be validated for other liver diseases, such as
hepatitis B or NAFLD.
 TE offers better performance for detecting cirrhosis
than significant fibrosis and is currently the standard
among non-invasive methods.
 In patients with cirrhosis, liver stiffness has a prog-
nostic value for the occurrence of portal hypertension.
However, TE cannot replace upper GI endoscopy for
the detection of esophageal varices.
 Current evidence suggests that TE could be used for
monitoring the response to antiviral treatment and for
predicting the prognosis of patients with chronic liver
disease.POINT SHEAR WAVE SPEED MEASUREMENT
(PSWSM) AND SHEARWAVE SPEED IMAGING
(SWSI)
Procedure
All technologies are implemented in a conventional
US system under direct visualization using a curved array
broadband transducer. A sample box is positioned on
B-mode image of the liver and elastography measure-
ments are obtained by pressing a button.
Optimal conditions include:
 Fasting;
 Dorsal decubitus position, with the right arm elevated
above the head for optimal intercostal access;
 Resting respiratory position (breath-hold without deep
inspiration);
 ROI placement beneath Glisson’s capsule by 1.5-2.0
cm to avoid reverberation artifacts and increased sub-
capsular stiffness;
 ROI placement to avoid large liver vessels;
 The median value of 5-10 measurements is considered
with PSWSM, and the mean value of 4 measurements
with SWSI.
Specific recommendations include:
 For SWSI, the sample box size should be large enough
to reduce the variation between measurements. This
provides a cumulative value that is the average of stiff-
ness at several points, thus being more representative
of the heterogeneous stiffness in abnormal and normal
livers.
 For PSWSM, the ROI should be placed perpendicular
to the center of the transducer surface as the angle of
insonation may have a slight but significant influence
on the result.Results
Point Shear Wave Speed Measurement. As of
today, there are two techniques: Virtual Touch Tissue
Quantification (VTTQ) technique that expresses the
results in m/sec (Figure 3) and ElastPQ that gives the
results in m/sec or in kPa (Figure 4). There are numerous
reports of studies performed using the VTTQ tech-
nique, which has been commercially available since
2009, but only a few using ElastPQ, which was intro-
duced in 2012.
The reproducibility of the VTTQ technique is
excellent, with an intraclass correlation coefficient
ranging from 0.84 to 0.87 (Bota et al. 2012; Boursier
et al. 2010; D’Onofrio et al. 2010; Guzman-Aroca et al.
2011). Operator training does not appear to be necessary
(Boursier et al. 2010). Similarly, the ElastPQ technique
is highly reproducible, with an interobserver agreement
ranging from 0.83 for comparison of single measure-
ments to 0.93 for the median value of 10 measurements
(Ferraioli et al. 2014).
In healthy volunteers, the values of PSWSM per-
formed with VTTQ are available in several publications
(D’Onofrio et al. 2010; Friedrich-Rust et al. 2009a;
Goertz et al. 2012; Grgurevic et al. 2011; Kaminuma
2011; Karlas 2011; Kim 2010; Kircheis 2012; Osaki
2010; Piscaglia 2011; Rifai 2011; Rizzo et al. 2011;
Son et al. 2012; Sporea et al. 2011; Takahashi et al.
2010). In all studies, the values were lower (, 1.2
m/sec) than in patients with chronic hepatitis. Food
intake significantly increases the liver stiffness values
(Goertz et al. 2012; Popescu et al. 2013).
Themedian value of PSWSMobtained with ElastPQ
in healthy volunteers is 3.5 kPa (Ling et al. 2013;
Ferraioli et al. 2014).
Chronic viral hepatitis. The range of cut-offs for
each fibrosis stage is quite large with overlap between
consecutive stages. The range of cut-offs for the fibrosis
stage ranges from 1.13 to 1.55 m/sec for F.2; from
1.43 to 1.81 m/sec for F.3; and from 1.36 to 2.13
m/sec for F4. The largest series comprises more than
600 patients withmixed etiologies of chronic liver disease
(Kircheis et al. 2012). Using TE as the reference method,
the investigators obtained cut-off values of 1.32 m/sec for
F2 and 1.62 m/sec for F4. Similar cut-offs were obtained
in the meta-analysis of Friedrich-Rust et al. (2012a), in
which nine studies were analyzed. Patients with chronic
liver disease of several etiologies were included, and the
cut-off values were 1.34, 1.55 and 1.80 m/sec, for signif-
icant fibrosis, severe fibrosis and cirrhosis, respectively.
PSWSM showed accuracy similar to that of TE for the
diagnosis of severe fibrosis, whereas a slightly but signif-
icantly higher diagnostic accuracy of TE with respect to
PSWSM was found for the diagnosis of significant
Figure 3. VTTQ technique in a healthy subject. Measurements of liver stiffness are given in m/sec; the sample box
is shown.
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analysis of Bota et al. (2013), in which thirteen studies
were included, PSWSM showed a predictive value similar
to TE for significant fibrosis and cirrhosis.
In an international multicenter study comprising
1,095 patients (181 with chronic hepatitis B and 914
with chronic hepatitis C), the correlation of PSWSM
with histological fibrosis was significantly higher in
patients with chronic hepatitis C compared with those
with chronic hepatitis B (r50.653 vs. r50.511,
p50.007), whereas both groups showed similar PSWSM
values for each fibrosis stage (Sporea et al. 2012).Figure 4. ElastPQ in a patient with chronic hepatitis C of F4Me
are expressed in kPa. Bottom left corner of the image: the stiffn
from soft toIn the study of Rizzo et al. (2011), using the PSWSM
cut-offs of 1.3 m/sec for the diagnosis of significant
fibrosis (F $ 2), 1.7 m/s for severe fibrosis (F $ 3), and
2.0 m/sec for cirrhosis (F 5 4), the highest concordance
was obtained for the diagnosis of mild fibrosis. TE may
overestimate the fibrosis stage in cases with severe liver
inflammation (Sagir et al. 2008; Arena et al. 2008). The
same limitation has been observed in some studies with
PSWSM (Takahashi et al. 2010; Yoon et al. 2012; Chen
et al. 2012), but not in others (Friedrich-Rust et al.
2009a; Palmeri et al. 2011; Rizzo et al. 2011;
Nishikawa et al. 2014).tavir stage on liver histology. The values of liver stiffness
ess is estimated and displayed by using a scale that ranges
hard.
WFUMB Guidelines for Ultrasound Elastography - Liver d G. FERRAIOLI et al. 1169The grade of liver steatosis appears not to influence
PSWSM (Friedrich-Rust et al. 2009a; Rizzo et al. 2011;
Rifai et al. 2011).
Measurement failure with PSWSM is reported in less
than 3% of patients (Friedrich-Rust et al. 2012a). No
invalid measurement occurred in the series of Rizzo et al.
(2011) and in the study of Crespo et al. (2012). PSWSM
provided valid results in all patients whereas TE failed in
11% of cases. In the series of Bota et al. (2014), reliable
measurements were obtained in 93.3% of cases. Older
age, higher BMI and male gender were associated with
the risk of failed and unreliable measurements.
A recent meta-analysis, which included either full
papers or abstracts for a total of 36 studies, has shown
that BMI has a significant influence for the diagnosis of
significant fibrosis (F $ 2) (Nierhoff et al. 2013). In
this meta-analysis, the diagnostic accuracy expressed as
the area under the ROC curve was 0.84, 0.89 and 0.91
for the diagnosis of significant fibrosis, advanced fibrosis,
and cirrhosis, respectively. Measurements are not limited
by ascites because the US push beam, which generates the
shear waves, propagates through fluids and appears not to
be influenced by clinical and biochemical variables
(Rizzo et al. 2011).
The possibility to evaluate several areas of the liver
parenchyma could be another advantage of PSWSM.
Indeed, histological studies have shown that liver fibrosis
is not homogeneously distributed within the liver, and can
be missed when performing liver biopsy at one site only,
thus leading to underestimation of liver fibrosis (Bedossa
et al. 2003; Maharaj et al. 1986). It should be noted that
D’Onofrio et al. (2010) reported significant differences
between intercostal and subcostal scans, and Kaminuma
et al. (2011) found that PSWSM were more reliable
when performed in a deep portion of the right lobe. In
their series of patients with chronic hepatitis, Toshima
et al. (2011) obtained significantly higher values in the
left lobe of the liver than the right lobe. It has been sug-
gested that oscillation of the left liver by cardiac activity
may interfere with stiffness measurements (Osaki et al.
2010).
Karlas T et al. (2011) found that, in healthy individ-
uals, the shear wave speed was higher in the left liver than
in the right, but no difference in speed was observed in pa-
tients with advanced fibrosis and cirrhosis. The authors
suggest that the absence of differences between the two
sides could be a criterion for the diagnosis of advanced
liver disease.
Preliminary results of PSWSM using ElastPQ in
102 patients with chronic hepatitis C have shown that
the accuracy of the method for staging liver fibrosis is
similar to that of TE and the best cut-off value for signif-
icant fibrosis (F$ 2) is 5.7 kPa (Ferraioli et al. 2014). In aseries of 291 patients with chronic hepatitis B, the
AUROCs for significant fibrosis and cirrhosis were 0.94
and 0.89, respectively (Ma et al. 2014).
Monitoring disease progression and prog-
nosis. Very few studies regarding disease progression
and prognosis have been published with conflicting re-
sults. In the cohort of Vermehren et al. (2012), the diag-
nostic accuracy of PSWSM of the liver and the spleen
for the prediction of esophageal varices was not signifi-
cantly different from that of TE and the Fibrotest; how-
ever, the AUROCs of all methods were fairly low,
ranging from 0.50 to 0.58. In the series of Morishita
et al. (2013), a cutoff value of 2.39 m/s had a sensitivity
of 81% and a specificity of 82% for detecting high-risk
esophageal varices.
In a recent study, a spleen stiffness value ,3.3 m/s
ruled out the presence of high-risk varices in patients
with compensated or decompensated liver cirrhosis (nega-
tive predictive value, 99.4%). Regardless of the etiologies
of liver disease, spleen stiffness was highly accurate for
the detection of esophageal varices (Takuma et al. 2013).
Nonalcoholic fatty liver disease (NAFLD). Only
few studies in small series of patients are available
(Yoneda et al. 2010; Osaki et al. 2010; Palmeri et al.
2011; Friedrich-Rust et al. 2012b; Fierbinteanu
Braticevici et al. 2013).
In 172 patients diagnosed with NAFLD, a cutoff of
4.24 kPa distinguished low (fibrosis stage 0–2) from
high (fibrosis stage 3–4) fibrosis stages with a sensitivity
of 90% and a specificity of 90% (AUROC 0.90) (Palmeri
et al. 2011). In a study on 61 patients with NAFLD/
NASH, the paired comparison of diagnostic accuracies
between TE and PSWSM for the diagnosis of significant
fibrosis, severe fibrosis and liver cirrhosis were similar
(Friedrich-Rust et al. 2012). In 64 patients with histolog-
ically proven NAFLD, the diagnostic performance of
PSWSM in predicting significant fibrosis and cirrhosis
had an AUROC of 0.94 and 0.98, respectively
(Fierbinteanu Braticevici et al. 2013).
Shear Wave Speed Imaging. SWSI expresses the re-
sults in m/sec or kPa (Figure 5). Ferraioli et al. (2012b)
found ICCs of 0.95 and 0.93 for expert and novice oper-
ators when comparing measurements performed on the
same day, and 0.84 and 0.65 for measurements performed
on different days. The interobserver agreement was 0.88.
These results have been confirmed in the recently pub-
lished study of Hudson et al. (2013). Like conventional
US, SWSI technology may be user dependent, so it is
recommended that at least 50 supervised scans and mea-
surements should be performed by a novice to obtain
consistent measurements (Ferraioli et al. 2012b).
Figure 5. SWSI technique in a patient with decompensated liver cirrhosis. Measurements of liver stiffness are given in
kPa. The mean value along with the minimum and maximum values and the standard deviation are shown.
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ported for histologically proven normal livers (Suh
et al. 2013).
In patients with chronic hepatitis C, cut-off values for
SWSI are reported in two publications based on 4
(Ferraioli et al. 2012c) or 5 (Bavu et al. 2011) measure-
ments from an intercostal space. Bavu et al. (2011) evalu-
ated 113 patients with chronic hepatitis C, comparing the
results to those obtainedwith TE; liver biopsywas not per-
formed. The results showed a good agreement between
fibrosis staging and elasticity assessment. SWSI showed
a higher accuracy in assessing mild and intermediate
stages of fibrosis. The diagnostic accuracy of SWSI in
the assessment of liver fibrosis in patients with chronic
hepatitis C was evaluated in a pilot study on 121 patients
(Ferraioli et al. 2012c). The optimal cut-off values of
SWSI were 7.1 kPa for significant fibrosis (F $ 2), 8.7
kPa for advanced fibrosis (F $ 3), and 10.4 kPa for
cirrhosis (F54). Areas under the ROC curves were 0.92
for F$ 2; 0.98 for F$ 3 and 0.98 for F54. A better per-
formance of SWSI compared to TE has also been observed
in 226 patients with chronic hepatitis B (Leung et al.
2013). In a study that evaluated liver fibrosis in a cohort
of 422 patients without a gold standard, Poynard et al.
(2013) report that the applicability of SWSI is lower
than that of TE whereas the performance of the two
methods is similar. In the same study, the applicability of
SWSI was higher than that of TE in patients with ascites.
It has been reported that stiffness values are not
correlated with liver steatosis (Ferraioli et al. 2012c;
Suh et al. 2013) or with necro-inflammation (Ferraioli
et al. 2012c).Limitations
- SWSI accuracy has only been assessed in the right lobe
through intercostal access. Interlobe variations of liver
stiffness have been reported with PSWSM. Body
habitus (obesity, narrow intercostal spaces) may ham-
per the results.
- Because of the frequency-dependency of the elasticity
properties of tissue, great care and consideration must
be used when comparing quantitative results among
these techniques.
- Results in kilopascals are not comparable between
SWSI, PSWSM and TE.
- The majority of the studies has been performed in
patients with chronic hepatitis C, therefore these cut-
offs may not be applicable to other viral etiologies or
to NAFLD. Only small series of patients with NAFLD
have been studied, therefore the cut-offs in these pa-
tients need further assessment.
- Readings may be higher in patients with ALT levels
greater than five times the upper limit of normal;
thus, the effect of inflammation should be taken into ac-
count, and the results should always be evaluated in the
clinical setting. As with TE, it is likely that congestive
heart failure, and feeding will be associated with a
stiffer liver.Recommendations
PSWSM and SWSI can be used to assess the severity
of liver fibrosis in patients with chronic viral hepatitis,
best evidenced in patients with hepatitis C. Nonetheless,
the evidence that is available is still limited, particularly
WFUMB Guidelines for Ultrasound Elastography - Liver d G. FERRAIOLI et al. 1171for SWSI. Like TE, PSWSM and SWSI are more accurate
in detecting cirrhosis than significant fibrosis.STRAIN ELASTOGRAPHY
Procedures
Scanning method. Successful real-time strain elas-
tography (SE) depends on the clarity of B-mode images -
the fundamental US images - and therefore, B-mode
images need to be of good quality and free from artifacts.
 Visualize the right liver through a right intercostal
space with the patient supine and the right arm elevated
to widen the intercostal spaces;
 Place the probe lightly on the skin without moving it,
since the method relies on intrinsic, mainly cardiac,
movement to displace the tissue;
 Select a region of interest in which B-mode images are
free from interfering structures;
 Obtain images displaying axial, not lateral, movement
by pointing the probe towards the heart;
 With a transient breath hold, make sure that SE images
are displayed consistently. (Fujimoto et al. 2013,
Morikawa et al. 2011, Tatsumi et al. 2010, Tatsumi
et al. 2008, Yada et al. 2013)
Region of Interest (ROI) placement. The manufac-
turer recommends that the ROI should be placed deep to
the liver capsule (Fujimoto et al. 2013, Morikawa et al.
2011, Tatsumi et al. 2010, Tatsumi et al. 2008, Yada
et al. 2013). Some researchers include the surrounding
tissues, such as the subcutaneous and muscle layers
(Kanamoto et al. 2009, Saftoiu et al. 2007); however,
placing the ROI entirely inside the liver is the key to
generate uniform images (Ferraioli et al. 2013,
Morikawa et al. 2011, Tatsumi et al. 2010, Yada et al.
2013). To avoid large blood vessels, imaging using a
2.5 3 2.5cm ROI is recommended (Fujimoto et al.
2013, Yada et al. 2013).
Elimination of artifacts requires attention to tech-
nique. The ROI should not include large blood vessels
to eliminate anechoic areas. It should not be placed close
to ribs or the liver capsule, or too deep in the parenchyma
as acoustic shadows, reverberation artifacts, and lack of
sufficient penetration will generate incorrect higher read-
ings. Experimentation with placement of the transducer
between the ribs will lead to the optimal positioning.
When an examination is difficult, it is recommended
to try another intercostal space, selecting one that is softer
and has a thinner subcutaneous layer. Other subcutaneous
structures, such as ribs and lungs, should not be included
in the image.
For the analysis, frames with strain generated in the
depth direction with no artifacts should be selected. Goodimages may be obtained at the end of diastole with elec-
trocardiographic gating or at the largest downward wave
on a strain graph.
Results
Reproducibility of the technique. The intra-observer
variability and intra-observer agreement of SE for the
assessment of liver fibrosis have been criticized in several
studies (Friedrich-Rust et al. 2009b; Saftoiu et al. 2007;
Ferraioli et al. 2007). In a recent study, a Japanese
group (Koizumi et al. 2011) used a semi-quantitative
method (elastic ratio) and found that the measurements
obtained from four separate locations had no observed
variation between the two operators (ICC 0.97).
Chronic hepatitis. In chronic hepatitis, the liver tis-
sue hardens unevenly as fibrosis advances. Accordingly,
if the ROI is placed only over the liver, it will highlight
the color variation of the SE images, emphasizing areas
with relatively low strain (blue areas). This generates im-
ages with a mottled appearance (Fig. 6) (Tatsumi et al.
2008, Yada et al. 2013).
Evaluation methods. The examiner’s experience
and subjectivity influence the outcome of visual assess-
ments. To overcome this, various quantitative methods
have been developed to assess tissue stiffness objectively.
 Image pattern recognition
Indices obtained by adjusting grayscale, histogram,
and binarization are called feature values, and are used
in pattern recognition. In SE imaging, feature values
given by the scanner or by separate imaging software
can be used to calculate correlations with liver fibrosis.
The strain estimate is converted to numerical values using
color gradations, with blue being 0 and red being 255.
Tatsumi et al. and Morikawa et al. have reported that
mean strain values inversely correlated with liver stiffness
and fibrosis in patients with chronic hepatitis C. On the
other hand, the standard deviation of mean values of
strain, the percentage of area of low strain and its
complexity were positively correlated with liver stiffness
and fibrosis (Morikawa et al. 2011, Tatsumi et al. 2008).
Calculation of function values
a. Liver Fibrosis (LF) Index
For the calculation of the LF index, nine features -
mean and standard deviation of the relative strain value,
complexity and ratio of the blue area in the ROI, skew-
ness, kurtosis, entropy, inverse difference moment,
angular second moment – are extracted (Fujimoto et al.
2013).
In a validation study of the LF Index using 245
patients with cirrhosis and chronic hepatitis B and C,
Figure 6. SE images of different stages of liver fibrosis in patients with chronic hepatitis C. The histogram displays the
color dispersion in the region of interest. The x-axis shows the color scale of the elastogram, coded from 0 (dark blue) to
255 (dark red); the y-axis shows the percentage of each color. LF index can be calculated on the ultrasound device. F1 (a),
F2 (b), F3 (c) and F4 fibrosis stage (d).
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advanced fibrosis and cirrhosis (AUROC 0.80) but not be-
tween other consecutive stages of liver fibrosis (Yada
et al. 2013).
LF index is a company-recommended standard ana-
lytic method.
The positive results obtained in the Japanese series
were not confirmed in other series (Ferraioli et al. 2012a).
b. Strain ratios
There are two types of evaluation methods that use
the strain ratio for analysis. The mainstream method
places the ROI only in the liver parenchyma for analysis
and calculates the ratio between the parenchyma and a
blood vessel. In another method, the ROI includes the
liver parenchyma and the surrounding tissue, and the
strain ratio between the two tissues is used in the
analysis.
Koizumi et al. (2011) imaged 70 chronic hepatitis C
patients with the ROI placed only in the liver paren-
chyma; they used the strain ratio (elastic ratio) between
the liver parenchyma and a peripheral hepatic vein forevaluation. The elastic ratio increased with the progres-
sion of liver fibrosis and was not affected by
inflammation.
In patients with NAFLD, Ochi et al. (2012) observed
a significant correlation between the elasticity ratio and
liver fibrosis. In addition, there was a significant differ-
ence in elasticity ratios between patients with NAFLD ac-
tivity score #4 and those with scores $ 5.
The elasticity ratio is not the manufacturer-
recommended technique for SE.
c. Other methods
In patients with hepatitis B and C, Friedrich-Rust
et al. calculated the tissue elasticity from every pixel in
SE images and performed multivariate analysis to obtain
a unique formula (Friedrich-Rust et al. 2007). Elasticity
scores calculated using that formula showed a significant
correlation with liver fibrosis. These results were not
confirmed in a more recent study by the same group
(Friedrich-Rust et al. 2009b).
 Influences other than liver fibrosis
WFUMB Guidelines for Ultrasound Elastography - Liver d G. FERRAIOLI et al. 1173SE can evaluate liver fibrosis without being affected
by inflammation, jaundice, and blood congestion. SE
evaluation is possible in patients with ascites (Hirooka
et al. 2011).Limitations
Various SE imaging and analysis methods are
currently available, and they all show a clear correlation
with liver fibrosis. However, a comparative study is
needed to reveal the best method. Although the technique
that uses cardiac activity as the driving force is most pop-
ular today, weak pulsation can adversely affect the quality
of SE images. Moreover, even though SE can be applied
to most cases because it can assess patients with ascites
and narrow intercostal spaces, it is difficult to generate
clear SE images in severely obese patients. It is also
necessary to learn to avoid artifacts. The experience
and skill of examiners can influence the accuracy of ultra-
sonography; however, variability among examiners with
proper training is reportedly low (Koizumi et al. 2011).
To expand the use of liver SE and further improve accu-
racy, the imaging and analysis methods need to be stan-
dardized and an effective SE training system needs to
be established. The current standard analytic method of
SE is the LF index ( Fujimoto et al. 2013, Yada et al.
2013).
Lastly, negative results should not be neglected
(Ferraioli et al. 2012a; Friedrich-Rust et al. 2009b).Recommendations
Objective assessment can be made only by the use of
the LF index.
Multicenter studies are currently being performed
and the results are anticipated.FOCAL LIVER MASSES
Diagnosis of focal liver masses is needed to identify
patients with malignant liver disease, to determine the
correct management and to differentiate these patients
from those with benign and insignificant pathology.
Although historically, these diagnoses were obtained
with liver biopsy, today we live in an era of noninvasive
diagnosis. For many years, contrast enhanced CT and
MR scans, and more recently contrast enhanced ultra-
sound (CEUS), have shown their value and ability to pro-
vide correct diagnoses without the requirement for
surgery or biopsy.
Currently, the use of elastography for characteriza-
tion of focal liver masses remains investigational. It is
hoped that elastography may supplement imaging to
give more specific diagnoses in selected patients.RECOMMENDATIONS
- Is elastography useful in the evaluation of diffuse
liver disease?
Liver elastography is useful for the evaluation of
diffuse liver diseases. The level of evidence is high for
TE, moderate for PSWSM, and still low for SWSI and
SE. Some methods have been used for more than ten
years while others have been introduced more recently,
resulting in large variability in the number of published
manuscripts on different techniques.
The majority of studies have evaluated patients with
viral chronic hepatitis and results obtained in this setting
may not be applicable to other clinical situations as the
critical cut-offs are strongly dependent on the etiology.
Values with shear wave-based elastography and with
strain techniques vary between manufacturers.
Thus, the cutoffs are both system and etiology
dependent.
Elastography is capable of distinguishing significant
fibrosis (F2 or greater) from non-significant (F0 - F1)
fibrosis. However, more data are needed to confirm its
use to distinguish between consecutive stages of early
fibrosis.
It is also important to note that each method may
provide different values expressed in different units (me-
ters per second, kilopascals) or indices.
Several confounding factors have been identified,
such as liver inflammation, liver congestion and biliary
obstruction.
Elastography results should be interpreted in the full
clinical context of the patient, taking into account the
method used to obtain the results.
Elastography can be used for follow-up of patients
with chronic liver diseases.
- Is the method reproducible?
Generally, the reproducibility of elastography tech-
niques is good. However, manufacturer recommendations
should be followed. Dedicated training is required for all
elastography methods.
- What is its accuracy in a range of pathologies?
The accuracy of elastography methods improves
with the severity of fibrosis. The most studied etiology
is chronic viral hepatitis. The body of evidence is highly
dependent on the method for other etiologies.
- What are the limitations?
Obesity is a common limitation of all ultrasound-
based elastographymethods. Other limitations are narrow
intercostal spaces and, for transient elastography, the
1174 Ultrasound in Medicine and Biology Volume 41, Number 5, 2015presence of ascites. Most methods show higher values
when the levels of aminotransferases are elevated.
Some manufacturers do not recommend the use of
liver elastography in pregnancy.
- To what extent can elastography reduce the use of
liver biopsies?
In some countries, where liver elastography is used
in clinical practice, the number of liver biopsies has
decreased significantly. When elastography results are
consistent with other clinical findings, liver biopsy may
be avoided.
- Can elastography provide additional information
for focal liver lesions?
Currently, the body of evidence concerning the use
of elastography in focal liver lesions is not strong enough
to recommend its use in clinical practice.
These recommendations are based on the interna-
tional literature and on the findings of the WFUMB
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